|
Mr. Archibald has spent three decades designing pivotal studies for industry and government, including 20 years at the Bristol-Myers Squibb Co. Pharmaceutical Research Institute. He last served as director of clinical biostatistics for neuroscience at BMS and previously was manager of clinical biostatistics for cardiovascular development. In these roles, he supervised statistical aspects of several sucessful regulatory filings, including NDAs, MAAs, and SNDAs. Before joining industry Mr. Archibald worked for the Veterans Administration, where he was lead statistician in a clinical study leading to the FDA’s original approval of aspirin to prevent recurrence of myocardial infarction. He was also lead statistician in the first clinical study to demonstrate that drugs could prolong survival in congestive heart failure. He holds multiple graduate degrees in statistics and mathematics from Yale University and Rensselaer Polytechnic Institute. | 